The US Court of Appeals for the Third Circuit rules on bundling in the pharmaceutical sector (Eisai / Sanofi Aventis)

Third Circuit Shows No Love For Lovenox® Bundling Theory* Citing the well-known maxim that the antitrust laws are concerned with “the protection of competition, not competitors,” the U.S. Court of Appeals for the Third Circuit on Wednesday affirmed summary judgment for Defendant Sanofi Aventis on Plaintiff Eisai, Inc.’s claim that Sanofi foreclosed competition in the market for anticoagulant drugs administered in hospitals. Eisai alleged that Sanofi dominated that market with its Lovenox® product. In addition to being FDA-approved for the treatment and prevention of deep-vein thrombosis (DVT), a potentially life-threatening condition

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Constantine Cannon (New York)

Quotation

Ankur Kapoor, The US Court of Appeals for the Third Circuit rules on bundling in the pharmaceutical sector (Eisai / Sanofi Aventis), 4 May 2016, e-Competitions May 2016, Art. N° 80228

Visites 310

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues